Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

NCT ID: NCT00194740

Last Updated: 2007-12-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-11-30
• Study Completion Date: 2007-06-30

Brief Summary

The two drugs used to treat metastatic breast cancer in this study may perform better when used together than when used separately. The use of another drug that prevents the most common side effect of the two-drug combination permits the delivery of both agents at closer to the "full" dose for either when used alone. We hypothesize that the two-drug combination used with G-CSF support will be more effective and less toxic than other standard regimens for the treatment of metastatic breast cancer.

Detailed Description

Preclinical data suggest that there may be synergy between vinorelbine and paclitaxel when the two drugs are used in combination such that the effect of the two together may be better than either alone. Clinical data suggest that the use of concurrent G-CSF with paclitaxel and vinorelbine permits the delivery of both agents at approximately 70% of the "full" dose for either, used alone without G-CSF support, with myelosuppression as the usual dose-limiting toxicity and no unusual or unexpected complications. Encouragingly, 8/20 (40%) patients had objective responses, with three complete remissions (15%) in this program of third-line therapy. Therefore, we now propose to combine docetaxel at about 70% of "full" dose with vinorelbine at 27.5 mg/m2, the "phase II" dose defined in the previous trial. Docetaxel will be given on day 1 followed by vinorelbine on days 8 and 15, with G-CSF to be administered on all days except that of docetaxel administration. The cycle is to be repeated every three weeks.

Conditions

Breast Neoplasm

Keywords

Breast cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

Docetaxel

Intervention Type: DRUG

60 mg/m2, IV, day 1 of each 21 day cycle

Vinorelbine

Intervention Type: DRUG

27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle

Filgrastim

Intervention Type: DRUG

5 µg/kg/day s.c., to be administered days 2-21 of each cycle.

Interventions

Docetaxel

60 mg/m2, IV, day 1 of each 21 day cycle

Intervention Type: DRUG

Vinorelbine

27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle

Intervention Type: DRUG

Filgrastim

5 µg/kg/day s.c., to be administered days 2-21 of each cycle.

Intervention Type: DRUG

Other Intervention Names

Taxotere; Navelbine; G-CSF, Neupogen

Eligibility Criteria

Inclusion Criteria

• Patients must have stage IV, microscopically-confirmed carcinoma of the breast with histologic slides and/or blocks available for review.
• Patients must have relapse or progression while receiving, or within 12 months of having received, anthracycline-containing (doxorubicin or mitoxantrone) regimen as either adjuvant treatment or therapy for advanced breast cancer. Prior Taxol by 3- or 24-hour infusion is permitted. Patients who have received a maximum dose of anthracycline (greater than 450 mg/m2) are also eligible.
• Patients must have measurable (bidimensionally) or evaluable disease.
• Patients must be 18 or more years of age.
• Patients must have a Karnofsky Performance Status greater than or equal to 70% at screen and on the first day of treatment.
• Patients must have a life expectancy of more than 16 weeks.
• Prior irradiation is permitted, provided that prior irradiation does not exceed 25% of the estimated bone marrow volume and provided that measurable/evaluable disease exists outside the radiation field OR there must be histologic proof of progressive disease within a radiation field.
• Informed consent must be obtained prior to registration.
• Patients must be more than 2 weeks from prior surgery; more than 3 weeks from radiation therapy to the pelvis, spine or long bones; more than 3 weeks from prior chemotherapy (more than 6 weeks for mitomycin C or nitrosureas), or more than 2 weeks from prior hormonal therapy.
• All patients must have appropriate central venous access.

Exclusion Criteria

Patients are excludes if their:

• Granulocyte count is less than 1,500/mm3.
• Platelet count is less than 100,000/mm3.
• Hemoglobin is less than 9 gm/dl.
• Creatinine is greater than 2.0 mg/dl.
• Total bilirubin is greater than ULN (institutional upper limit of normal)..
• SGOT (AST) and/or SGPT (ALT) is greater than 1.5 x ULN concomitant with alkaline phosphatase greater than 2.5 x ULN.

Patients are excluded if they are:

• In visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases.
• Medically unstable.
• Pregnant or lactating.

Patients are excluded if they have:

• Uncontrolled CNS disease.
• Pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer.
• Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol.
• Prior therapy with Navelbine.
• Sensitivity to E. Coli-derived proteins.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aventis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

University of Washington

OTHER

Sponsor Role: lead

Responsible Party

University of Washington

Principal Investigators

Julie R. Gralow, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

University of Washington/Seattle Cancer Care Alliance

Seattle, Washington, United States

Countries

United States

Other Identifiers

97-5372-A

Identifier Type: -

Identifier Source: org_study_id